RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
ROCKET PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.24+0.06 (+2.75%)
Close on Oct 19, 2026
- Market cap
- $256.51M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.47 (−39.62%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ROCKET PHARMACEUTICALS, INC. reported revenue of $0 for the twelve months to Jun 30, 2026. Free cash flow was -$170.39M.
Revenue
$0
TTM Q2 2026
Operating income
-$191.64M
TTM Q2 2026
Free cash flow
-$170.39M
TTM Q2 2026
EPS, diluted
-$0.17
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $256.51M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.70
- Dividend yield
- –
- Free cash flow yield
- -66.43%
Fundamentals
- Revenue
- $0
- Net income
- -$17.25M
- EPS, diluted
- -$0.17
- Free cash flow
- -$170.39M
- Book value per share
- $3.22
- Diluted shares
- 115M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$0
Operating income
-$191.64M
Net income
-$17.25M
EPS, diluted
-$0.17
Free cash flow
-$170.39M
Reported periodTrailing twelve months